The industry looks set to bring the first vaccine for RSV to market in the coming year. But, which companies are leading the race, and why it would mark an important development for global health?
As Pear Therapeutics’ financial situation forces the company into bankruptcy, Ben Hargreaves takes a look at whether this is just a blip on the road for digital therapeutics, or a sign of d
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
